

**National Pharmaceutical Pricing Authority**

**Subject: Minutes of the 72<sup>nd</sup> meeting of the Multidisciplinary Committee of Experts held on 09.10.2025 at 3:00 PM.**

72<sup>nd</sup> meeting of the Multidisciplinary Committee of Experts was held on 09.10.2025 at 3:00 PM under the convenorship of Shri Sanjay Kumar, Advisor (Cost). The following members attended the meeting:

1. Shri Ranga Chandrashekar, Joint Drugs Controller, CDSCO, through Video Conferencing
2. Dr. Rakesh Kr. Singh, Professor & Dean, NIPER Raebareli, through Video Conferencing
3. Prof. Y. K. Gupta, Principal Scientific Advisor (Projects), THSTI-DBT, GoI & Ex-HoD, Pharmacology & Dean (Academics), AIIMS, New Delhi – Co-opted member, through Video Conferencing
4. Dr. Jai Prakash, Sr. Principal Scientific Officer, Indian Pharmacopoeia Commission – Co-opted member,

The following officers of NPPA attended and presented the cases before the Committee:

1. Ms. Rashmi Tahiliani, Director (Pricing)
2. Shri Mahaveer Saini, Deputy Director (Pricing)
3. Ms. Yuvika Panwar, Assistant Director (Pricing)
4. Shri Bhiva Ram Yadav, Assistant Director (Pricing & Overcharging)
5. Shri Mayur Panwar, Assistant Director (Pricing)

**Agenda Item No. 1: Application for approval of separate ceiling price for scheduled drugs under special features (Euro Head) by M/s Safal Lifescience Private Limited (Manufacturer) and M/s One Drip Healthcare Private Limited (Marketer)**

1. The Committee noted that M/s Safal Lifescience Private Limited (Manufacturer) and M/s One Drip Healthcare Private Ltd. applied on 17.06.2025 for separate ceiling prices under Para 11(3) of the DPCO, 2013 (complete application received on 20.08.2025) mentioning that their following IV fluids packaged in LDPE bottle with Euro Head have special features of Self collapsibility, self-seal-ability, secure closure, sterility, clear labeling and material selection etc.:

| <b>S. No.</b> | <b>Name of Product</b>                                                                     | <b>Pack Size</b> | <b>Brand Name</b> |
|---------------|--------------------------------------------------------------------------------------------|------------------|-------------------|
| 1.            | Dextrose Injection IP 5% w/v – 500ml LDPE Bottle with EURO Head                            | 500ml            | DRIPEURO          |
| 2.            | Sodium Chloride Injection IP 0.9% w/v – 100ml LDPE Bottle with EURO Head                   | 100ml            | DRIPEURO          |
| 3.            | Sodium Chloride Injection IP 0.9% w/v – 500ml LDPE Bottle with EURO Head                   | 500ml            | DRIPEURO          |
| 4.            | Dextrose 5% w/v + Sodium Chloride 0.9% w/v Injection IP – 500ml LDPE Bottle with EURO Head | 500ml            | DRIPEURO          |
| 5.            | Compound Sodium Lactate Injection IP – 500ml LDPE Bottle with EURO Head                    | 500ml            | DRIPEURO          |

2. The Committee noted that the matter was deliberated in 71<sup>st</sup> meeting held on 16.09.2025, wherein the Committee directed that the authorized person of the company who is well-versed with the documents and claims submitted may be asked to appear before the Committee in next meeting to present their case and demonstrate the product for special features claimed in the application. Accordingly, the applicant companies appeared before the Committee and demonstrated its products.

3. The Committee examined the documents relating to flow rate analysis, certificate of analysis for plastic used in manufacturing of the plastic containers for the applied formulations. The Committee noted that the product bears the features of self-sealability, self-collapsibility and has a dual port to prevent the contamination. Accordingly, the Committee recommended the separate ceiling price for the following formulations:

| S. No. | Name of Product                         | Pack Size | Applicable ceiling price w.e.f. 01.04.2025<br>(S.O. No. & Date) |
|--------|-----------------------------------------|-----------|-----------------------------------------------------------------|
| 1.     | Dextrose Injection IP 5% w/v            | 500ml     | 83.70/pack<br>(1485(E) dt.27.03.2025)                           |
| 2.     | Sodium Chloride Inj 0.9% w/v            | 100ml     | 42.79/pack<br>(1485(E) dt.27.03.2025)                           |
| 3.     | Sodium Chloride Inj 0.9% w/v            | 500ml     | 89.47/pack<br>(1485(E) dt.27.03.2025)                           |
| 4.     | Dextrose 5% + Sodium Chloride 0.9% Inj. | 500ml     | 87.01/pack<br>(1485(E) dt.27.03.2025)                           |
| 5.     | Compound Sodium Lactate Injection       | 500ml     | 66.09/pack<br>(1474(E) dt.27.03.2025)                           |

**Agenda Item No. 2: Application for approval of separate ceiling prices under Para 11(3) of the DPCO, 2013 for Dual Port Bottles of Large Volume Parenteral by M/s Life Infusion Pharmaceuticals Pvt. Ltd.**

1. The Committee noted that M/s Life Infusion Pharmaceuticals Pvt. Ltd. applied on 29.07.2025 for separate ceiling prices under Para 11(3) of the DPCO, 2013 for their dual port products mentioning that their LVP products have special features with dual port in plastic collapsible bottles through ISBM technology and they have fully automated system for manufacturing to avoid man intervention to prevent cross contamination to prepare the good quality products:

| S. No. | Name of Product                                                                                                                   | Pack Size |
|--------|-----------------------------------------------------------------------------------------------------------------------------------|-----------|
| 1.     | Metronidazole Injection: Each 100ml contains Metronidazole 0.5g                                                                   | 100ml     |
| 2.     | Dextrose Injection IP 5% w/v: Each 100ml contains Dextrose Anhydrous IP 5g                                                        | 500ml     |
| 3.     | Dextrose Injection IP 5% w/v: Each 100ml contains Dextrose Anhydrous IP 5g                                                        | 1000ml    |
| 4.     | Dextrose Injection IP 5% w/v & Sodium Chloride 0.9% w/v: Each 100ml contains Dextrose Anhydrous IP 5gm & Sodium Chloride IP 900mg | 500ml     |
| 5.     | Dextrose Injection IP 5% w/v & Sodium Chloride 0.9% w/v: Each 100ml contains Dextrose Anhydrous IP 5gm & Sodium Chloride IP 900mg | 1000ml    |
| 6.     | Sodium Chloride 0.9% w/v: Each 100ml contains: Sodium Chloride IP 0.9g                                                            | 100ml     |

| S. No. | Name of Product                                                          | Pack Size |
|--------|--------------------------------------------------------------------------|-----------|
| 7.     | Sodium Chloride 0.9% w/v: Each 100ml contains: Sodium Chloride IP 0.9g   | 500ml     |
| 8.     | Sodium Chloride 0.9% w/v: Each 100ml contains: Sodium Chloride IP 0.9g   | 1000ml    |
| 9.     | Compound Sodium Lactate Injection                                        | 500ml     |
| 10.    | Compound Sodium Lactate Injection                                        | 1000ml    |
| 11.    | Mannitol Injection 20%: Each 100ml contains Mannitol IP 20g              | 100ml     |
| 12.    | Dextrose Injection IP 25%: Each 100ml contains Dextrose anhydrous IP 25g | 100ml     |
| 13.    | Ciprofloxacin Injection IP (0.2% w/v)                                    | 100ml     |

2. The Committee noted that the matter was deliberated in 71<sup>st</sup> meeting held on 16.09.2025, wherein the Committee directed that the authorized person of the company who is well-versed with the documents and claims submitted may be asked to appear before the Committee in next meeting to present their case and demonstrate the product for special features claimed in the application. Accordingly, the applicant company appeared before the Committee and demonstrated its products.

3. The Committee examined the documents relating to flow rate analysis, certificate of analysis for plastic used in manufacturing of the plastic containers for the applied formulations. The Committee noted that the product has the features of self-sealability, self-collapsibility and has a twin port to prevent the contamination. Accordingly, the Committee recommended the separate ceiling price for the following formulations:

| S. No. | Name of Product                                                                                                                   | Pack Size | Applicable ceiling price<br>w.e.f. 01.04.2025<br>(S.O. No. & Date) |
|--------|-----------------------------------------------------------------------------------------------------------------------------------|-----------|--------------------------------------------------------------------|
| 1.     | Metronidazole Injection: Each 100ml contains Metronidazole 0.5gm                                                                  | 100ml     | 0.25/ml<br>(1486(E) dt. 27.03.25)                                  |
| 2.     | Dextrose Injection IP 5% w/v: Each 100ml contains Dextrose Anhydrous IP 5gm                                                       | 500ml     | 83.70/pack<br>(1485(E) dt. 27.03.25)                               |
| 3.     | Dextrose Injection IP 5% w/v: Each 100ml contains Dextrose Anhydrous IP 5gm                                                       | 1000ml    | 96.77/pack<br>(1485(E) dt. 27.03.25)                               |
| 4.     | Dextrose Injection IP 5% w/v & Sodium Chloride 0.9% w/v: Each 100ml contains Dextrose Anhydrous IP 5gm & Sodium Chloride IP 900mg | 500ml     | 87.01/pack<br>(1485(E) dt. 27.03.25)                               |
| 5.     | Dextrose Injection IP 5% w/v & Sodium Chloride 0.9% w/v: Each 100ml contains Dextrose Anhydrous IP 5gm & Sodium Chloride IP 900mg | 1000ml    | 101.68/pack<br>(1485(E) dt. 27.03.25)                              |
| 6.     | Sodium Chloride 0.9% w/v: Each 100ml contains: Sodium Chloride IP 0.9gm                                                           | 100ml     | 42.79/pack<br>(1485(E) dt. 27.03.25)                               |
| 7.     | Sodium Chloride 0.9% w/v: Each 100ml contains: Sodium Chloride IP 0.9gm                                                           | 500ml     | 89.47/pack<br>(1485(E) dt. 27.03.25)                               |
| 8.     | Sodium Chloride 0.9% w/v: Each 100ml contains: Sodium Chloride IP 0.9gm                                                           | 1000ml    | 100.22/pack<br>(1485(E) dt. 27.03.25)                              |

| S. No. | Name of Product                                                           | Pack Size | Applicable ceiling price<br>w.e.f. 01.04.2025<br>(S.O. No. & Date) |
|--------|---------------------------------------------------------------------------|-----------|--------------------------------------------------------------------|
| 9.     | Compound Sodium Lactate Injection                                         | 500ml     | 66.09/pack<br>(1474(E) dt. 27.03.25)                               |
| 10.    | Compound Sodium Lactate Injection                                         | 1000ml    | 116.20/pack<br>(1474(E) dt. 27.03.25)                              |
| 11.    | Mannitol Injection 20%: Each 100ml contains Mannitol IP 20gm              | 100ml     | 0.41/ml<br>(1486(E) dt. 27.03.25)                                  |
| 12.    | Dextrose Injection IP 25%: Each 100ml contains Dextrose anhydrous IP 25gm | 100ml     | 0.24/ml<br>(1486(E) dt. 27.03.25)                                  |
| 13.    | Ciprofloxacin Injection IP (0.2% w/v)                                     | 100ml     | 0.23/ml<br>(1486(E) dt. 27.03.25)                                  |

**Agenda Item No. 3: Application for separate ceiling price for IV fluids in special features under the provisions of Para 11 of the DPCO, 2013 by M/s Virchow Biotech Private Limited**

1. The Committee noted that M/s Virchow Biotech Private Limited applied on 10.09.2025 for separate ceiling prices under Para 11(3) of the DPCO, 2013 stating that their IV fluids packaged in Dual port **LVP bags**, bear special features viz. (i) self-collapsibility and self-sealability, (ii) preventing vacuum build up (iii) having no chance of contamination during manufacture / infusion / admixing level, for the following formulations:

| S. No. | Name of Product                                                                                                                   | Pack Size | Claimed MRP ex. GST |
|--------|-----------------------------------------------------------------------------------------------------------------------------------|-----------|---------------------|
| 1      | Sodium Chloride 0.9% w/v: Each 100ml contains: Sodium Chloride IP 0.9gm                                                           | 100ml     | 42.79               |
| 2      | Sodium Chloride 0.9% w/v: Each 100ml contains: Sodium Chloride IP 0.9gm                                                           | 250ml     | 63.18               |
| 3      | Sodium Chloride 0.9% w/v: Each 100ml contains: Sodium Chloride IP 0.9gm                                                           | 500ml     | 89.47               |
| 4      | Sodium Chloride 0.9% w/v: Each 100ml contains: Sodium Chloride IP 0.9gm                                                           | 1000ml    | 100.22              |
| 5      | Dextrose Injection IP 5% w/v : Each 100ml contains Dextrose Anhydrous IP 5gm                                                      | 500ml     | 83.70               |
| 6      | Dextrose Injection IP 5% w/v : Each 100ml contains Dextrose Anhydrous IP 5gm                                                      | 1000ml    | 96.77               |
| 7      | Compound Sodium Lactate Injection                                                                                                 | 500ml     | 66.09               |
| 8      | Dextrose Injection IP 5% w/v & Sodium Chloride 0.9% w/v: Each 100ml contains Dextrose Anhydrous IP 5gm & Sodium Chloride IP 900mg | 500ml     | 87.01               |
| 9      | Dextrose Injection IP 5% w/v : Each 100ml contains Dextrose Anhydrous IP 5gm                                                      | 250ml     | 34.00               |
| 10     | Dextrose Injection IP 10% w/v : Each 100ml contains Dextrose Anhydrous IP 10gm                                                    | 500ml     | 42.00               |
| 11     | Dextrose Injection IP 10% w/v : Each 100ml contains Dextrose Anhydrous IP 10gm                                                    | 1000ml    | 39.00               |

| S. No. | Name of Product                                                                                                                   | Pack Size | Claimed MRP ex. GST |
|--------|-----------------------------------------------------------------------------------------------------------------------------------|-----------|---------------------|
| 12     | Dextrose Injection IP 5% w/v & Sodium Chloride 0.9% w/v: Each 100ml contains Dextrose Anhydrous IP 5gm & Sodium Chloride IP 900mg | 250ml     | 34.00               |

2. The Committee noted that the matter was deliberated in 71<sup>st</sup> meeting held on 16.09.2025, wherein the Committee directed that the authorized person of the company who is well-versed with the documents and claims submitted may be asked to appear before the Committee in next meeting to present their case and demonstrate the product for special features claimed in the application. Accordingly, the applicant company appeared before the Committee and demonstrated its products. During the discussion in the meeting, the applicant requested to withdraw the application for four formulations listed at S. No. 9 to 12 of above table.

3. The Committee examined the documents relating to flow rate analysis, certificate of analysis for plastic used in manufacturing of the LVP bags for the applied formulations, excluding the formulation for which the company requested for withdrawal. The Committee noted that the product i.e. LVP bags containing the respective products bear the features of self-sealability, self-collapsibility and have dual ports to prevent the contamination. Accordingly, the Committee recommended the separate ceiling price for the following formulations:

| S. No. | Name of Product                                                                                                                   | Pack Size | Applicable ceiling price w.e.f. 01.04.2025 (S.O. No. & Date) |
|--------|-----------------------------------------------------------------------------------------------------------------------------------|-----------|--------------------------------------------------------------|
| 1      | Sodium Chloride 0.9% w/v: Each 100ml contains: Sodium Chloride IP 0.9gm                                                           | 100ml     | 42.79<br>(1485(E) dt. 27.03.25)                              |
| 2      | Sodium Chloride 0.9% w/v: Each 100ml contains: Sodium Chloride IP 0.9gm                                                           | 250ml     | 63.18<br>(1485(E) dt. 27.03.25)                              |
| 3      | Sodium Chloride 0.9% w/v: Each 100ml contains: Sodium Chloride IP 0.9gm                                                           | 500ml     | 89.47<br>(1485(E) dt. 27.03.25)                              |
| 4      | Sodium Chloride 0.9% w/v: Each 100ml contains: Sodium Chloride IP 0.9gm                                                           | 1000ml    | 100.22<br>(1485(E) dt. 27.03.25)                             |
| 5      | Dextrose Injection IP 5% w/v: Each 100ml contains Dextrose Anhydrous IP 5gm                                                       | 500ml     | 83.70<br>(1485(E) dt. 27.03.25)                              |
| 6      | Dextrose Injection IP 5% w/v: Each 100ml contains Dextrose Anhydrous IP 5gm                                                       | 1000ml    | 96.77<br>(1485(E) dt. 27.03.25)                              |
| 7      | Compound Sodium Lactate Injection                                                                                                 | 500ml     | 66.09<br>(1474(E) dt. 27.03.25)                              |
| 8      | Dextrose Injection IP 5% w/v & Sodium Chloride 0.9% w/v: Each 100ml contains Dextrose Anhydrous IP 5gm & Sodium Chloride IP 900mg | 500ml     | 87.01<br>(1485(E) dt. 27.03.25)                              |

**Agenda Item No. 4: Application for extension of separate ceiling prices under Para 11(3) of the DPCO, 2013 for IV fluid in Euro Head with packaging in non-glass with special feature by M/s Klokter Life Sciences Pvt. Ltd. (manufacturer) and Zee Laboratories Limited (marketer)**

1. The Committee noted that M/s Klokter Life Sciences Pvt. Ltd. (manufacturer) and Zee Laboratories Limited (marketer) applied on 09.09.2025 for separate ceiling prices under Para 11(3) of the DPCO,

2013 stating that their IV fluids packaged in Euro Head bottles, which incorporate special features viz. (i) self-collapsibility and self-sealability, (ii) not having air-vent, (iii) having no chance of contamination during manufacture / infusion / admixing level, for the following formulations:

| S. No. | Name of Product                                                                                                                   | Pack Size | Applicable ceiling price w.e.f. 01.04.2025 (S.O. No. & Date) |
|--------|-----------------------------------------------------------------------------------------------------------------------------------|-----------|--------------------------------------------------------------|
| 1.     | Dextrose Injection IP 5% w/v : Each 100ml contains Dextrose Anhydrous IP 5gm                                                      | 500ml     | 1485(E) dt. 27.03.25                                         |
| 2.     | Dextrose Injection IP 5% w/v & Sodium Chloride 0.9% w/v: Each 100ml contains Dextrose Anhydrous IP 5gm & Sodium Chloride IP 900mg | 500ml     | 1485(E) dt. 27.03.25                                         |
| 3.     | Sodium Chloride 0.9% w/v: Each 100ml contains: Sodium Chloride IP 0.9gm                                                           | 500ml     | 1485(E) dt. 27.03.25                                         |
| 4.     | Compound Sodium Lactate Injection                                                                                                 | 500ml     | 1474(E) dt. 27.03.25                                         |

2. The Committee noted that the matter was deliberated in 71<sup>st</sup> meeting held on 16.09.2025, wherein the Committee directed that the authorized person of the company who is well-versed with the documents and claims submitted may be asked to appear before the Committee in next meeting to present their case and demonstrate the product for special features claimed in the application. Accordingly, the applicant manufacturer company appeared before the Committee and demonstrated its products.

3. The Committee examined the documents relating to flow rate analysis, certificate of analysis for plastic used in manufacturing of the plastic containers for the applied formulations. The Committee noted that the product bears the features of self-sealability, self-collapsibility and has dual port to prevent the contamination. Accordingly, the Committee recommended the separate ceiling price for the following formulations:

| S. No. | Name of Product                                                                                                                   | Pack Size | Ceiling price ex. GST                |
|--------|-----------------------------------------------------------------------------------------------------------------------------------|-----------|--------------------------------------|
| 1.     | Dextrose Injection IP 5% w/v : Each 100ml contains Dextrose Anhydrous IP 5gm                                                      | 500ml     | 83.70/pack<br>(1485(E) dt. 27.03.25) |
| 2.     | Dextrose Injection IP 5% w/v & Sodium Chloride 0.9% w/v: Each 100ml contains Dextrose Anhydrous IP 5gm & Sodium Chloride IP 900mg | 500ml     | 87.01/pack<br>(1485(E) dt. 27.03.25) |
| 3.     | Sodium Chloride 0.9% w/v: Each 100ml contains: Sodium Chloride IP 0.9gm                                                           | 500ml     | 89.47/Pack<br>(1485(E) dt. 27.03.25) |
| 4.     | Compound Sodium Lactate Injection                                                                                                 | 500ml     | 66.09/Pack<br>(1474(E) dt. 27.03.25) |

The meeting ended with a vote of thanks to all.

(Rashmi Tahiliani)  
Director (Pricing)

Copy to:  
All members of the Committee.